The proportion of patients with CI-AKI events was 5.3% (13 out of 245) in the SGLT2 inhibitor user cohort and 121 out of 1,265 (9.6%) in the whole nonuser cohort (Table 1). Here, SLC5A2 is linked to acute kidney injury.